Stay updated on Pembrolizumab Combo in Premenopausal HR+/HER2- Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab Combo in Premenopausal HR+/HER2- Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab Combo in Premenopausal HR+/HER2- Breast Cancer Clinical Trial page

  1. Check
    3 days ago
    Change Detected
    Summary
    The page's revision label was updated from v3.6.5 to v3.6.6, indicating the latest version of the study record.
    Difference
    0.0%
    Check dated 2026-09-02T19:51:39.000Z thumbnail image
  2. Check
    10 days ago
    Change Detected
    Summary
    Added '2019 ( U.S. NIH Grant/Contract )' in the Study ID Numbers section after the EudraCT number, indicating U.S. NIH funding.
    Difference
    0.0%
    Check dated 2026-08-26T21:00:08.000Z thumbnail image
  3. Check
    17 days ago
    No Change Detected
  4. Check
    24 days ago
    Change Detected
    Summary
    The page's revision tag was updated from Revision: v3.6.4 to Revision: v3.6.5, indicating a small metadata update to the page.
    Difference
    0.0%
    Check dated 2026-08-13T01:37:25.000Z thumbnail image
  5. Check
    46 days ago
    Change Detected
    Summary
    The page footer now displays the revision tag updated from v3.6.3 to v3.6.4, signaling a newer version of the page. This is a routine maintenance update with no substantive content changes.
    Difference
    0.0%
    Check dated 2026-07-22T13:53:48.000Z thumbnail image
  6. Check
    67 days ago
    Change Detected
    Summary
    The page now shows Revision: v3.6.3, replacing Revision: v3.6.0. This indicates an internal update to the page or its documents rather than a change to the study data.
    Difference
    0.0%
    Check dated 2026-07-01T02:36:37.000Z thumbnail image
  7. Check
    81 days ago
    Change Detected
    Summary
    New user-guidance sections were added and recruitment status updated to No longer looking for participants; the Intervention/Treatment heading is standardized and a Revision: v3.6.0 tag is introduced while the old v3.5.5 tag is removed.
    Difference
    0.1%
    Check dated 2026-06-16T18:35:16.000Z thumbnail image

Stay in the know with updates to Pembrolizumab Combo in Premenopausal HR+/HER2- Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in Premenopausal HR+/HER2- Breast Cancer Clinical Trial page.